Creo Medical Group PLC Director/PDMR Dealing (5908B)
April 04 2017 - 11:47AM
UK Regulatory
TIDMCREO
RNS Number : 5908B
Creo Medical Group PLC
04 April 2017
Creo Medical Group plc
Director/PDMR Dealing
The Company has been informed that directors Craig Gulliford
(Chief Executive Officer) and Chris Hancock (Chief Technology
Officer) have today each transferred ordinary shares of 0.1p each
("Ordinary Shares") in the Company from their personal holdings to
their self-invested personal pensions ("SIPP"), as follows.
Director Number of Price per Number of Price paid
Ordinary Ordinary Ordinary per Ordinary
Shares sold Share sold Shares purchased Share by
from personal into SIPP SIPP
account
----------------- --------------- ------------ ------------------ --------------
Craig Gulliford 92,750 82.5p 92,704 82.5p
----------------- --------------- ------------ ------------------ --------------
Chris Hancock 106,084 82.5p 106,038 82.5p
----------------- --------------- ------------ ------------------ --------------
Following these transactions, Mr Gulliford and Mr Hancock's
total interest in the Company are 1,089,886 Ordinary Shares and
4,880,150 Ordinary Shares respectively.
Template for notification and public disclosure of transactions
by persons discharging managerial responsibilities and persons
closely associated with them
1 Details of the person discharging managerial
responsibilities / person closely associated
--- ------------------------------------------------------------
a) Name Craig Gulliford
--- ------------------------- ---------------------------------
2 Reason for the notification
--- ------------------------------------------------------------
a) Position/status Chief Executive Officer
--- ------------------------- ---------------------------------
b) Initial notification Initial
/Amendment
--- ------------------------- ---------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
--- ------------------------------------------------------------
a) Name Creo Medical Group plc
--- ------------------------- ---------------------------------
b) LEI N/A
--- ------------------------- ---------------------------------
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
--- ------------------------------------------------------------
a) Description of
the financial Ordinary shares of GBP0.001
instrument, type each
of instrument
Identification GB00BZ1BLL44
code
--- ------------------------- ---------------------------------
b) Nature of the Transfer of ordinary shares
transaction to self-invested personal
pension (SIPP) via sale and
purchase
--- ------------------------- ---------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
------------------ ----------
Sale of shares
from personal
holding at
82.5p per share 92,750
------------------ ----------
Purchase by
SIPP at 82.5p
per share 92,704
------------------ ----------
--- ------------------------- ---------------------------------
d) Aggregated information
- Aggregated volume
Weighted average price of
82.5p per share
- Price
--- ------------------------- ---------------------------------
e) Date of the transaction 4 April 2017
--- ------------------------- ---------------------------------
f) Place of the transaction London Stock Exchange
--- ------------------------- ---------------------------------
1 Details of the person discharging managerial
responsibilities / person closely associated
--- ------------------------------------------------------------
a) Name Chris Hancock
--- ------------------------- ---------------------------------
2 Reason for the notification
--- ------------------------------------------------------------
a) Position/status Chief Technology Officer
--- ------------------------- ---------------------------------
b) Initial notification Initial
/Amendment
--- ------------------------- ---------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
--- ------------------------------------------------------------
a) Name Creo Medical Group plc
--- ------------------------- ---------------------------------
b) LEI N/A
--- ------------------------- ---------------------------------
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
--- ------------------------------------------------------------
a) Description of
the financial Ordinary shares of GBP0.001
instrument, type each
of instrument
Identification GB00BZ1BLL44
code
--- ------------------------- ---------------------------------
b) Nature of the Transfer of ordinary shares
transaction to self-invested personal
pension (SIPP) via sale and
purchase
--- ------------------------- ---------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
------------------ ----------
Sale of shares
from personal
holding at
82.5p per share 106,084
------------------ ----------
Purchase by
SIPP at 82.5p
per share 106,038
------------------ ----------
--- ------------------------- ---------------------------------
d) Aggregated information
- Aggregated volume
Weighted average price of
82.5p per share
- Price
--- ------------------------- ---------------------------------
e) Date of the transaction 4 April 2017
--- ------------------------- ---------------------------------
f) Place of the transaction London Stock Exchange
--- ------------------------- ---------------------------------
Contacts
Creo Medical: Cenkos: FTI Consulting:
Roseanne Varner Ivonne Cantu Brett Pollard
+44 (0)129 160 6005 / Camilla Hume / Mo Noonan
roseanne.varner@creomedical.com (NOMAD) +44 (0)203 727
Michael Johnson 1000
/ Russell Kerr creo@fticonsulting.com
(Sales)
+44 (0)207 397
8900
About Creo Medical
Creo Medical, founded in 2003, is a medical device company
focused on the development and commercialisation of minimally
invasive surgical devices, by bringing advanced energy to
endoscopy. The Company's mission is to improve patient outcomes by
applying microwave and radiowave energy to surgical endoscopy. Creo
has developed CROMA, an electrosurgical platform that combines
bipolar radiofrequency for precise localised cutting and microwave
for controlled coagulation. This technology provides physicians
with flexible, accurate and controlled surgical solutions.
The Company's strategy is to bring the CROMA surgical system to
market through a suite of medical instruments which the Company has
designed, initially for GI therapeutic endoscopy, an area with high
unmet needs. The CROMA system will be developed further for
bronchoscopy and laparoscopy procedures. The Company believes its
technology can impact the landscape of surgery and endoscopy by
providing safer, less-invasive and more cost-efficient option of
treatment.
For more information about Creo Medical please see our website,
www.creomedical.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHEAKLLELSXEFF
(END) Dow Jones Newswires
April 04, 2017 12:47 ET (16:47 GMT)
Creo Medical (LSE:CREO)
Historical Stock Chart
From Apr 2024 to May 2024
Creo Medical (LSE:CREO)
Historical Stock Chart
From May 2023 to May 2024